Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts

To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18–75). The average ti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2023-10, Vol.118 (4), p.462-471
Hauptverfasser:	Takagi, Erina, Terakura, Seitaro, Fujigaki, Hidetsugu, Okamoto, Akinao, Miyao, Kotaro, Sawa, Masashi, Morishita, Takanobu, Goto, Tatsunori, Ozawa, Yukiyasu, Nishida, Tetsuya, Fukushima, Nobuaki, Ozeki, Kazutaka, Hanajiri, Ryo, Saito, Kuniaki, Murata, Makoto, Tomita, Akihiro, Kiyoi, Hitoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Allografts Antibodies Antibody response COVID-19 Hematology Hematopoietic stem cells Immunization Immunoglobulin M Medicine Medicine & Public Health mRNA Oncology Original Article Severe acute respiratory syndrome coronavirus 2 Stem cell transplantation Stem cells Transplantation Transplants & implants Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18–75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5–15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (
ISSN:	0925-5710 1865-3774
DOI:	10.1007/s12185-023-03648-1